Drugs / Tyvyt
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04096690 | Sep 2019 → Dec 2021 | extranodal nasal NK/T cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tyvyt | “Tyvyt” NCT04096690 ↗ |
| Action | Inhibit | “Anti-PD-1 antibody” NCT04096690 ↗ |
| Modality | Monoclonal antibody | “Anti-PD-1 monoclonal antibody” NCT04096690 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT04096690 ↗ |